LANREOTIDE, LANREOTIDE, Debio 4126, Debio 4126, Ready-to-use suspension resembling 30, 60, or 90 mg Debio 4126 doses, Debio 4126, OCTREOTIDE, OCTREOTIDE, LANREOTIDE, OCTREOTIDE
Debio 4126-301
Phase 3 small_molecule active
Quick answer
LANREOTIDE, LANREOTIDE, Debio 4126, Debio 4126, Ready-to-use suspension resembling 30, 60, or 90 mg Debio 4126 doses, Debio 4126, OCTREOTIDE, OCTREOTIDE, LANREOTIDE, OCTREOTIDE for Acromegaly is a Phase 3 program (small_molecule) at Pharm Research Associates (UK) Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharm Research Associates (UK) Limited
- Indication
- Acromegaly
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active